Zentrela

Zentrela operates at the intersection of neurotechnology, neuroscience, AI, and cannabis consumer research. Its stated focus is measuring psychoactive effects through brainwave analysis, rather than relying only on product attributes or reported consumer impressions. Cognalyzer combines EEG data with AI algorithms, while the CUSIC method brings together consumer profiles, product properties, and consumption information. The company also describes a data-as-a-service model in which product-effect findings can support producers’ research and business decisions. This creates a specialized position within cannabis research, where its proposed differentiator is standardized, objective measurement of consumer experience. Zentrela’s stated evidence base includes peer-reviewed validation, and its intellectual-property profile lists one granted patent and four registered trademarks. The company is private, reports a team size of 1–10 employees, and has raised $2.9 million across five recorded rounds. These indicators suggest a focused, small-scale specialist rather than a broad research-services provider, though public information about commercial reach and market adoption is limited.

Zentrela was founded in August 2015 and built its financing history through a mix of early Seed support and grants. The recorded rounds begin with a Seed round on Nov 30, 2016, followed by a $50,000 Seed round on Jun 28, 2019 and a $1 million grant on Jul 21, 2019. A further $1 million grant followed on Mar 2, 2020, before Jornic Ventures led an $850,000 Seed round announced on Feb 11, 2021. Structured funding totals $2.9 million across five rounds; an alternative financial overview gives a lower $2.05 million figure, so the total should be treated with that discrepancy in mind. Product development centers on Cognalyzer, the CUSIC Consumer Research Method, and a data-as-a-service approach. The listed employee range is 1–10, and leadership roles span science, commercial affairs, and strategic business affairs alongside founder and CEO Israel Gasperin. The evidence therefore supports a trajectory of early research development and targeted financing, but provides limited visibility into present-day revenue, adoption, or expansion.